心房颤动中局灶性激活的消融 (RETRO-AF)
持续性心房颤动期间局灶激活的消融以确定局灶驱动因素的特征
Recurrent focal electrical activation (or ectopy) superseding sinus activation is the only mechanism proven to drive paroxysmal atrial fibrillation (AF). However, it has not been possible to show similar focal drivers during AF, owing to the limitations of mapping in persistent AF. RETRO-Mapping has been developed as a method to generate activation maps during AF to test the hypothesis that persistent AF is also maintained by focal drivers.
RETRO-Mapping is able to locate sites of focal activation that were isolated, intermittent, or recurrent during persistent AF. However, a 30-second segment of AF can have approximately 150 wavefronts in a small area of myocardium. Screening for focal activation and manually validating these prior to ablation was not feasible using current commercial systems.
RETRO-Mapping can automatically detect focal activation and a recording system that enables the intracardiac signals to be directly analysed by the RETRO-Mapping software. This will allow RETRO-Mapping to build a detailed classification of focal activation types and study the impact of ablation of these sites on the AF cycle length, to address the hypothesis that persistent AF is maintained by focal drivers.
研究概览
地位
详细说明
Multiple large, prospective randomised controlled trials have shown that pulmonary vein isolation (PVI) terminates AF in 50-70% of cases. The continued presence of atrial fibrillation (AF) in those without demonstrable reconnection on a mapping catheter suggests other mechanisms at play. However, outside PV ectopy, drivers of AF initiation or maintenance remain unclear.
Detailed mapping studies have confirmed the presence of both focal activation and spatiotemporally stable planar wavefronts during AF, with limited data suggesting focal activation may drive AF. This study is based on the hypothesis that focal activation may lead to planar wavefronts at its origin, which subsequently disintegrate on exposure to refractory myocardium in different locations, and assumes that randomised studies of adjunctive ablation have shown poor results to date because excessive ablation has been performed at non-driver sites and this ablation scar is pro-arrhythmic.
RETRO-Mapping is a novel algorithmic solution to AF mapping with published validation confirming accuracy of analysis of activation wavefronts, when benchmarked against laborious manual annotation. RETRO-Mapping found that nearly 30% of mapped sites contained focal activation, and these ranged from single events to repetitive events that could either be consecutive or interspersed with other activation patterns. This study now aims to characterise multiple different activation patterns that exist within the milieu of AF, and interrogate their role in the initiation and maintenance of AF by randomising patients to adjunctive ablation of sites of focal activation, versus usual care alone (i.e., PVI).
The effect of this adjunctive ablation on AF cycle length will be the primary outcome measure, and freedom from AF will be a secondary outcome measure. AF termination is usually considered a positive endpoint for adjunctive ablation, but, as a single event, cannot help identify which part of the adjunctive ablation approach led to this useful outcome. By contrast, left atrial appendage and coronary sinus cycle length prolongation can be used as continuous measures of progress towards AF termination, and may allow determination of whether focal activation sites are drivers of persistent AF, and whether the characteristics of focal activation alter the likelihood of it being a driver.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Prapa Kanagaratnam, FRCP PhD
- 电话号码:020 3312 6666
- 邮箱:p.kanagaratnam@imperial.ac.uk
研究联系人备份
- 姓名:Oliver S Jones, MRCP
- 邮箱:o.jones@imperial.ac.uk
学习地点
-
-
-
London、英国、W12 0HS
- 招聘中
- Hammersmith Hospital
-
接触:
- Oliver S Jones, MRCP
- 邮箱:o.jones@imperial.ac.uk
-
接触:
- Prapa Kanagaratnam, PhD FRCP
- 电话号码:020 3312 6666
- 邮箱:p.kanagaratnam@imperial.ac.uk
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Persistent atrial fibrillation with clinical indication for catheter ablation
- Clinically suitable candidate for catheter ablation
- Signed informed consent
Exclusion Criteria:
- Previous atrial fibrillation or other catheter ablation procedure
- Clinical contraindication to catheter ablation or general anaesthetic, including history of adverse reaction to contrast media, or presence of intracardiac thrombus, or inadequate anticoagulation in the preceding 6 weeks
- Valvular disease graded moderate or greater, or presence of a prosthetic valve
- Moderate-to-severe heart failure, defined as left ventricular ejection fraction <35% and/or New York Heart Association class III-IV
- Any form of cardiomyopathy
- Active infection or fever
- Severe cerebrovascular disease
- Active gastrointestinal bleeding
- Bleeding or clotting disorders, clinically high bleeding risk, or clinical contraindication to receiving heparin
- Baseline serum creatinine >200umol/L
- Currently receiving or at risk of requiring renal replacement therapy
- Uncontrolled diabetes (HbA1c ≥73mmol/mol or HbA1c ≤64mmol/mol and fasting blood glucose ≥9.2mmol/L)
- Malignancy necessitating therapy
- Life expectancy shorter than the duration of the trial
- Pregnancy, or childbearing potential and not using a highly effective method of contraception
- Inability to provide informed consent to participate in the trial
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
安慰剂比较:Pulmonary vein isolation with diagnostic RETRO-Mapping only
All patients will undergo standard pulmonary vein isolation (PVI) procedures with 3D electroanatomic mapping using the CARTO™ system (Biosense Webster, USA), or the EnSite X™ system (Abbott, USA). A decapolar catheter will be inserted into the coronary sinus. A 3D electroanatomic map of the left atrium will be created and all pulmonary veins will be identified. Radio-frequency ablation will be performed to achieve PVI. After the PVI procedure, patients in the control arm will have the same mapping for identification and categorisation of focal sources, but no adjunctive ablation. RETRO-Mapping will be performed using custom-built hardware called Tau20 that has been validated for reproducibility against existing commercial technologies. |
Standard clinical radio-frequency ablation isolation of pulmonary veins RETRO-Mapping performed using research equipment and software, but without any adjunctive ablation |
|
实验性的:Pulmonary vein isolation with adjunctive ablation guided by RETRO-Mapping
In addition to and after the PVI procedure, patients the intervention arm will then have RETRO-Mapping performed of the remaining atria and atrial fibrillation cycle length measured in coronary sinus and left atrial appendage. Each segment will be mapped for 30 seconds and the activation pattern categories; if focal activation is identified, it will then be ablated. A further 30 seconds will be mapped at the same segments post-ablation to determine effect. The coronary sinus and left atrial appendage cycle length will be documented at the start of RETRO-Mapping and after each lesion set. |
Standard clinical radio-frequency ablation isolation of pulmonary veins Radio-frequency ablation using a European conformity (CE)-marked ablation catheter of sites of focal activation identified by RETRO-Mapping |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Atrial fibrillation cycle length in coronary sinus and left atrial appendage
大体时间:Intra-procedural
|
Measurement of atrial fibrillation cycle length in coronary sinus and left atrial appendage, measured in miliseconds |
Intra-procedural
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Freedom from atrial fibrillation
大体时间:1 year
|
Follow-up after a 3-month blanking period. Recurrence of atrial arrhythmia at 3, 6, 9, and 12 months with a 24-hour Holter monitor, or at any point over same period with an AliveCor KardiaMobile, will be recorded. Measurements across differing devices will be aggregated to give a single time-to-recurrence measurement, given in days. |
1 year
|
合作者和调查者
调查人员
- 首席研究员:Prapa Kanagaratnam, FRCP PhD、Imperial College London
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.